PMC:7352545 / 71690-71883 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T695","span":{"begin":98,"end":104},"obj":"Body_part"}],"attributes":[{"id":"A695","pred":"fma_id","subj":"T695","obj":"http://purl.org/sig/ont/fma/fma62970"}],"text":"ddition, Mab therapy is another option. For example, LCA50 Mab mimics produced by modification of plasma antibodies isolated from MERS-CoV patients was valuable [140]. Low molecular molecules a"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1036","span":{"begin":98,"end":104},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"}],"text":"ddition, Mab therapy is another option. For example, LCA50 Mab mimics produced by modification of plasma antibodies isolated from MERS-CoV patients was valuable [140]. Low molecular molecules a"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T52765","span":{"begin":182,"end":191},"obj":"Chemical"}],"attributes":[{"id":"A88714","pred":"chebi_id","subj":"T52765","obj":"http://purl.obolibrary.org/obo/CHEBI_25367"}],"text":"ddition, Mab therapy is another option. For example, LCA50 Mab mimics produced by modification of plasma antibodies isolated from MERS-CoV patients was valuable [140]. Low molecular molecules a"}

{"project":"LitCovid-sentences","denotations":[{"id":"T695","span":{"begin":40,"end":167},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ddition, Mab therapy is another option. For example, LCA50 Mab mimics produced by modification of plasma antibodies isolated from MERS-CoV patients was valuable [140]. Low molecular molecules a"}

{"project":"2_test","denotations":[{"id":"32604730-30684561-51944107","span":{"begin":162,"end":165},"obj":"30684561"},{"id":"T85859","span":{"begin":162,"end":165},"obj":"30684561"}],"text":"ddition, Mab therapy is another option. For example, LCA50 Mab mimics produced by modification of plasma antibodies isolated from MERS-CoV patients was valuable [140]. Low molecular molecules a"}